You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
A highly potent and selective D4 dopamine receptor antagonist; L-745,870 has Ki values of 0.51, 2300 and 960 nM for D4, D3 and D2 subtypes respectively and > 1000-fold selectivity over 5-HT2, D1 and D5 receptors.
Sold with the permission of Merck Sharp and Dohme Ltd.
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 436.21. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.29 mL||11.46 mL||22.92 mL|
|5 mM||0.46 mL||2.29 mL||4.58 mL|
|10 mM||0.23 mL||1.15 mL||2.29 mL|
|50 mM||0.05 mL||0.23 mL||0.46 mL|
References are publications that support the biological activity of the product.
Bristow et al (1997) Schizophrenia and L-745, 870 a novel DA D4 receptor antagonist. TiPS 18 186 PMID: 9226994
Kulagowski et al (1996) 3-[[4-(4-Chlorophenyl)piperazin-1-yl]methyl-1H-pyrrolo[2,3-b]pyridine: an antagonist with high affinity and selectivity for the human D4 receptor. J.Med.Chem. 39 1941 PMID: 8642550
Patel et al (1997) Biological profile of L-745,870, a selective antagonist with high affinity for the DA D4 receptor. J.Pharmacol.Exp.Ther. 283 636 PMID: 9353380
Pillai et al (1998) Human D2 and D4 DA receptors couple through βγ G-protein subunits to inwardly rectifying K+ channels (GIRK1) in a Xenopus oocyte expression system: selective antagonism by L-741,626 and L-745,870 respect Neuropharmacology 37 983 PMID: 9833627
If you know of a relevant reference for L-745,870 trihydrochloride, please let us know.
View Related Products by Product Action
Keywords: L-745,870 trihydrochloride, L-745,870 trihydrochloride supplier, selective, D4, antagonists, Dopamine, Receptors, dopaminergic, L745870, 1002, Tocris Bioscience
12 Citations for L-745,870 trihydrochloride
Citations are publications that use Tocris products. Selected citations for L-745,870 trihydrochloride include:
Basso et al (2005) Antidepressant-like effect of D(2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test. Neuropsychopharmacology 30 1257 PMID: 15688083
Huang (2017) Neurochemical arguments for the use of DA D4 receptor stimulation to improve cognitive impairment associated with schizophrenia. Pharmacol Biochem Behav 157 16 PMID: 28455127
Chen et al (2015) Activation of D4 DA receptor decreases angiotensin II type 1 receptor expression in rat renal proximal tubule cells. Autophagy 65 153 PMID: 25368031
Herwerth et al (2012) D4 DA receptors modulate NR2B NMDA receptors and LTP in stratum oriens of hippocampal CA1. Cereb Cortex 22 1786 PMID: 21955919
Okada et al (2005) A DA D4 receptor antagonist attenuates ischemia-induced neuronal cell damage via upregulation of neuronal apoptosis inhibitory protein. Hypertension 25 794 PMID: 15729293
Guo (2017) DA D4 receptor activation restores CA1 LTP in hippocampal slices from aged mice. Aging Cell 16 1323 PMID: 28975698
Dai et al (2017) Is DA transporter-mediated DArgic signaling in the retina a noninvasive biomarker for attention-deficit/ hyperactivity disorder? A study in a novel DA transporter variant Val559 transgenic mouse model. J Neurodev Disord 9 38 PMID: 29281965
Jensen (2015) Effects of DA D2-Like Receptor Antagonists on Light Responses of Ganglion Cells in Wild-Type and P23H Rat Retinas. PLoS One 10 e0146154 PMID: 26717015
Suárez-Boomgaard et al (2014) DA D4 receptor counteracts morphine-induced changes in µ opioid receptor signaling in the striosomes of the rat caudate putamen. Int J Mol Sci 15 1481 PMID: 24451133
Steullet et al (2014) Fast oscillatory activity in the anterior cingulate cortex: DArgic modulation and effect of perineuronal net loss. Front Cell Neurosci 8 244 PMID: 25191228
Matsui and Alvarez (2018) Cocaine Inhibition of Synaptic Transmission in the Ventral Pallidum Is Pathway-Specific and Mediated by Serotonin. Cell Rep 23 3852 PMID: 29949769
Picton et al (2016) Mechanisms underlying the endogenous DArgic inhibition of spinal locomotor circuit function in Xenopus tadpoles. Scientific Reports 6 35749 PMID: 27760989
Do you know of a great paper that uses L-745,870 trihydrochloride from Tocris? Please let us know.
Reviews for L-745,870 trihydrochloride
Average Rating: 5 (Based on 1 Review.)
Have you used L-745,870 trihydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
L-745870 (100 nM)
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.